mL at 48 weeks versus 31% of patients in the ABC+3TC+ZDV arm. These differences in higher viral load suggest that there may be decreased potency in a three-drug NRTI regimen.
In a meta-analysis of virologic failures from four clinical trials, among participants who received therapies containing ABC and ZDV, the K65R and L74V mutations were seen in <2% of participants. 2 In contrast, among participants who received ABC without ZDV, the K65R mutation was observed in approximately 10% of these participants. These results suggested that the presence of ZDV may delay emergence of K65R, a resistance-conferring RT mutation that is associated with reduced susceptibility to all currently approved nucleosides/nucleotides with the exception of ZDV. 3 We therefore conducted a pilot study of a quadruple-NRTI regimen consisting of a fixed dose combination (FDC) of ABC/3TC/ZDV (TZV; Trizivir ® ) and a fourth NRTI, tenofovir disoproxil fumarate (300 mg) (TDF; Viread ® ), in antiretroviralnaïve individuals with high baseline HIV-1 RNA (≥30,000 copies/mL) to be administered once daily (qd). Although the ABC/3TC/ZDV FDC was not approved for once-daily dosing, clinical studies have demonstrated equivalent or noninferior virologic efficacy for once-daily and twice-daily dosing of ABC 4 and 3TC. 5 At the time the present study was initiated, a proof-of-concept study provided supporting evidence of antiviral activity of once-daily ZDV. 6 The study showed that ZDV 600 mg qd had antiviral activity, although it was less pronounced than that seen with ZDV 300 mg bid (0.6 log 10 copies/mL vs. 0.9 log 10 copies/mL after 14 days of dosing). Based on this evidence, we postulated that the combination of ABC/3TC/ZDV with TDF might (a) augment antiviral potency of the regimen, and (b) confer additional resistance benefit since viruses containing the M184V mutation have shown hypersusceptibility to TDF in vitro. 3, 7 
METHOD

Study Population
Antiretroviral-naïve male and female participants ≥18 and ≤65 years of age with HIV-1 documented by ELISA and confirmed by Western blot, positive HIV-1 blood culture, positive serum antigen, or plasma viremia were eligible for inclusion into this study. Participants had to provide written informed consent, have an entry plasma HIV RNA ≥30,000 copies/mL (Roche Amplicor ® HIV-1 Monitor TM kit; Roche Diagnostic Systems, Inc., Branchburg, New Jersey, USA) within 21 days prior to study enrollment, and not have an AIDSdefining illness within 30 days of screening. Women able to conceive were required to have a negative serum pregnancy test at screening and to use adequate birth control during the study. The study was approved by the institutional review boards for each site, and all participants provided written informed consent.
Study Design
This was a nonrandomized, single-arm, openlabel, observational study conducted at 11 centers in the United States. Participants received the coformulated FDC ABC/3TC/ZDV (300/150/300 mg, Trizivir ® ; GlaxoSmithKline, North Carolina, USA) (2 tablets qd) + TDF (300 mg, Viread ® ; Gilead Sciences, California, USA) (1 tablet qd) for 48 weeks. Participants who met confirmed virologic nonresponse, defined as two consecutive viral load assessments ≥400 copies/mL at week 24 or later, were required to discontinue the study.
Following reports of a high number of virologic failures (49%, 63%) in participants receiving ABC/ 3TC+TDF in two studies, 8, 9 an unplanned interim analysis was performed for this study. Although our analysis did not demonstrate that there was a high rate of virologic failures, 10 the original study protocol was amended to allow participants to switch therapy as an additional safety measure. Participants were allowed to replace TDF with lopinavir/ritonavir (400/100 mg co-formulation: 3 capsules twice daily [bid], with food) if they met any of the following protocol-defined switch criteria: ≥1 log 10 copies/mL increase in plasma HIV-1 RNA above nadir between week 8 and week 24 (virologic rebound); plasma HIV-1 RNA ≥400 copies/mL at week 24 or later (virologic nonresponse); plasma HIV-1 RNA between 50 and 400 copies/mL at week 16 or later (incomplete virologic response). All plasma HIV-1 RNA levels had to be confirmed by a second measurement 2 to 4 weeks after the first measurement.
Assessments
Plasma samples were assayed for HIV-1 RNA using the Roche Amplicor HIV-1 Monitor™ ultrasensitive assay, version 1.0 (lower limit of detection: 50 copies/mL) and standard assay (lower limit of detection: 400 copies/mL). Blood counts included CD4+ and CD8+ subset analyses. Plasma HIV-1 RNA concentration, CD4+ and CD8+ cell counts, hematology, and clinical chemistry were performed at screening, on day 1, and at weeks 4, 8, 16, 24, 32, 40 , and 48. An additional plasma HIV-1 RNA measurement was taken at week 2. Blood samples were analyzed for fasting glucose, total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglycerides at weeks 8, 24, and 48. Safety was measured by clinical and laboratory evaluations. The severity of adverse events and laboratory abnormalities was graded according to the AIDS Clinical Trials Group (ACTG) toxicity scale. 11 All laboratory tests were performed centrally by Quest Diagnostics (Van Nuys, California, USA).
Peripheral blood mononuclear cells (PBMCs) were collected on day 1 (baseline) and week 48 to assess changes in mitochondrial DNA copy number. 12 Mitochondrial DNA analyses were assessed at GlaxoSmithKline (Research Triangle Park, North Carolina, USA). HIV-1 genotyping and phenotyping were performed on baseline samples from all participants at GlaxoSmithKline (Research Triangle Park, North Carolina, USA) while for virologic failures, HIV-1 genotyping and phenotyping were performed for samples up through the time of confirmed virologic nonresponse and at the time of study withdrawal by Virco (Michelen, Belgium). Self-reported adherence was assessed by the Patient Medication Adherence Questionnaire (PMAQ-3W): perfect adherence to each study drug/regimen was measured by the responses to the four questions in Part 2 of PMAQ-3W.
Statistical Analysis
The intent-to-treat (ITT) population was the primary population used for all efficacy analyses and was defined to include all enrolled participants in the study. The planned primary endpoint for the study was the proportion of participants with HIV-1 RNA <50 copies/mL by week 24, evaluated using the ITT population observed (ITT Obs) rate. The ITT Obs rate includes only observed assessments in the calculation of the rate; missing assessments are not imputed and are not included in the calculation of the rate. The ITT missing equals failure (M=F) rate imputes failures for missing assessments. The proportion of participants who achieved <400 copies/mL and <50 copies/mL in plasma HIV-1 RNA at week 48 were estimated. The baseline, week 48 PBMC levels, and week 48 change in PBMC levels from baseline were also summarized. Safety summaries were performed on the safety population, which consisted of all participants who had taken at least one dose of study drug. The number and percent of participants who had grades 3 and 4 adverse events or laboratory toxicities were summarized. In addition, the measured and change from baseline values were summarized for fasting lipids, including total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and glucose.
A planned interim analysis was performed at week 24.
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RESULTS
Baseline Characteristics and Patient Accountability
A total of 123 participants were enrolled from July 2002 to August 2004. The demographics and baseline characteristics of study participants are shown in Table 1 . Seventy-one subjects (58%) completed 48 weeks of therapy, and 52 (42%) withdrew from the study prematurely ( Table 2) . Of the 14 withdrawals due to adverse events, 8 cases were due to suspected hypersensitivity reaction (HSR) to ABC. One patient switched from TDF to lopinavir/ritonavir treatment after meeting the protocol-defined criteria for switching from the study treatment. One participant died of Kaposi's sarcoma during the study. Of the 52 premature discontinuations, approximately half of the discontinuations were judged to be unrelated to study drugs, including lost to follow-up, consent withdrawal, protocol violations, and other reasons. Protocol violations included noncompliance and being off study medications for prolonged periods. Three participants prematurely discontinued for other reasons, including lack of efficacy, incarceration, and relocation to another state.
Plasma HIV RNA
At week 48, the proportion of participants who achieved a plasma HIV-1 RNA level of <50 copies/ mL was 41% (51/123; ITT: M=F) and 75% (51/68; ITT: Obs) (see Figure 1A) . The proportion of participants with plasma HIV-1 RNA level of <400 copies/ mL was 51% (63/123; ITT: M=F) and 93% (63/68; ITT: Obs) (see Figure 1B) . When participants were stratified by baseline HIV-1 RNA, a lower proportion of participants achieved virologic suppression among those with high baseline HIV-1 RNA (≥100,000 copies/mL) compared with those with low baseline HIV-1 RNA (<100,000 copies/mL) ( Figures 1A and 1B) . Overall, 14 participants (11%) met virologic nonresponse criteria; of these, 12 (86%) had baseline plasma HIV-1 RNA ≥100,000 copies/ mL, consistent with the lower virologic response rates among those with high baseline HIV-1 RNA.
CD4+ and CD8+ cell counts
By week 48, the CD4+ cell count increased with a median of 127 cells/mm 3 (range, -173 to 515; n = 67). The CD8+ cell count decreased by a median of 109 cells/mm 3 (range, -1586 to 813; n = 67).
Safety
Suspected ABC HSR was reported in eight (6.5%) participants: three females and five males (three whites, two Hispanics, three blacks). All eight cases occurred within the first 3 weeks of Figure 1 . Proportion of participants achieving plasma HIV-1 RNA (A) <400 copies/mL and (B) <50 copies/mL by week 48 according to an intent-to-treat (ITT) analyses: missing = failure (M=F) and observed (Obs). Results are also stratified by baseline (BL) viral load (VL) ≥100,000 copies/mL or <100,000 copies/mL. n Obs all = VL < 100K = VL ≥ 100K = study drug administration, and all cases resolved without sequelae upon discontinuation of drug. Fifteen percent (18/123) of participants experienced a grade 3 or 4 adverse event. The most common grade 3 or 4 adverse events (occurring in ≥2% of participants) were drug hypersensitivity (4%; n = 5) and nausea (2%; n = 2).
Treatment-emergent grade 3 or 4 laboratory toxicities were reported in 11% (14/123) of participants. The most common grade 3 or 4 laboratory abnormalities (occurring in ≥2% of participants) were increases in serum lipase (3%, 4/122), alanine aminotransferase (2%, 3/122), aspartate aminotransferase (2%, 2/122), and gamma glutamyl transferase (GGT) (2%, 2/122) and decreases in white blood cell count (2%, 2/121) and platelets (2%, 2/121). The majority of patients in this study (97%; 119/123) did not experience disease progression.
Fasting Lipids
Median changes from baseline in fasting lipid values through week 48 are shown in Figure 2 . The median decrease from baseline in total cholesterol and LDL cholesterol concentrations was 9 mg/dL (each). The median decrease from baseline in triglycerides was 3.5 mg/dL. A small increase from baseline was noted in HDL cholesterol (1 mg/dL).
Mitochondrial DNA Level
Of the 54 participants who had the mitochondrial DNA measured at baseline, 16 had a second measurement at week 48. A median change of 0.02 was noted in the mitochondrial DNA concentration for these 16 participants: 291 copies/cell (baseline) and 285 copies/cell (week 48).
Adherence
Adherence to each study drug/regimen was assessed by the four questions in Part 2 of PMAQ-3W. A "no" answer to all four questions was considered "perfect" adherence to the study drug or regimen. Perfect adherence to the combination ABC/3TC/ZDV+TDF regimen was reported in 71% of participants (81/113). Of the virologic nonresponders, only about half (8/14) reported being perfectly adherent at weeks 4, 24, and 48 by PMAQ-3W part 2.
DISCUSSION
This single-arm pilot study demonstrated that a high rate of premature discontinuations contributed to the overall low virologic suppression rates to once-daily ABC/3TC/ZDV+TDF; however, the regimen was not associated with high rates of virologic failure previously observed with TDF+ABC/ 3TC. For those participants who remained on study, once-daily regimen ABC/3TC/ZDV+TDF had antiviral efficacy and a favorable lipid profile. At 48 weeks, 51% and 93% of participants achieved sustained plasma HIV-1 RNA concentrations of <400 copies/mL (ITT: M=F and ITT: Obs analyses, respectively). The proportions of participants with <50 plasma HIV-1 RNA copies/mL at 48 weeks were lower but equally disparate for the two types of analyses (41% and 75% for ITT: M=F and ITT: Obs analyses, respectively). The disparity in virologic response rates by the different ITT analyses reflects the high rate of discontinuations in this study due to multiple factors, most of which were judged unrelated to study drugs.
The results from this study indicate that, despite ZDV being dosed once-daily, the ABC/3TC/ ZDV+TDF regimen was not associated with early virologic nonresponse or high rates of virologic failure previously observed with the TDF+ABC/ 3TC regimen in other studies. In the present study, virologic nonresponse was noted in 11% (14/123) of participants over the 48-week study period. An earlier unplanned interim analysis showed that 8 of 88 participants (15%) with at least 8 weeks of HIV-1 RNA data had met protocol-defined virologic nonresponse, including 7 with baseline HIV-1 RNA ≥100,000 copies/mL but only 1 with baseline HIV-1 RNA <100,000 copies/mL. 10 These results are in contrast to those reported for three studies involving the TDF+ABC+3TC qd combination. [14] [15] [16] Two studies were prematurely interrupted when virologic failure criteria were met in 63% (12/17) of participants 14 and in 49% (50/102) of participants. 16 In the study by Landman et al., 15 33% (12/36) participants had virologic failure at week 24. Suboptimal results were also reported for the combinations of TDF+ddI+3TC, 17 ABC+ddI+d4T, 18, 19 or ABC+ddI+3TC. 20 In the DART study, which is a large, randomized study evaluating first-line therapy of ZDV/3TC (Combivir ® ) and TDF in patients with high baseline HIV-1 RNA and ad- vanced disease, 55% (165/300) of participants had HIV-1 RNA <50 copies/mL and 65% (196/300) had HIV-1 RNA < 400 copies/mL by ITT M=F analysis at 48 weeks. 21 These findings, along with the resistance data reported for our study, 22 suggest that resistance development occurs by a different pathway for ABC/3TC/ZDV+TDF compared with that for TDF+ABC/3TC, resulting in a lower incidence of virologic failure. Our findings also suggest that the clinical utility of the beneficial interaction between ZDV and TDF should be explored in future investigations. The use of ZDV and TDF in initial therapy is limited by the greater efficacy benefit seen with twice-daily therapies and the widespread adoption of once-daily therapies. However, second-line regimens with TDF combined with ZDV may be a useful model to evaluate this interaction as a means of prolonging both TDF activity and utilizing the additional antiviral benefit of ZDV.
The safety and activity of a quadruple-NRTI regimen consisting of ABC/3TC/ZDV and TDF have been evaluated in a number of small studies. In a study by Moyle and colleagues in antiretroviral-naïve participants, 23 a higher 48-week virologic response rate was reported in their randomized study of ABC/3TC/ZDV bid plus TDF qd than the present study: 67% (38/57) and 97% (55/57) of participants achieved plasma HIV-1 RNA <50 copies/mL (ITT: M=F and ITT: as treated, respectively). The difference in response rates between the two studies may be due to differences in dosing schedules of ABC/3TC/ZDV used for the two studies. In ACTG 5095, among participants who were originally randomized to ABC/3TC/ ZDV and had HIV-1 RNA <200 copies/mL, among those who intensified treatment with TDF, 22% (19/85) of participants reached protocol-defined treatment failure at 72 weeks. 24 ABC/3TC/ ZDV+TDF has also been evaluated in antiretroviral-naïve participants by retrospective analysis 25 and in treatment-experienced participants by both retrospective and prospective analyses. [26] [27] [28] In the Greiger-Zanlungo analysis, 88% (22/ 25) of participants with baseline HIV-1 RNA of 4.7 log 10 copies/mL and baseline CD4 of 331 cells/mL had HIV-1 RNA <50 copies/mL after 16 months on treatment.
In this study, no unexpected or clinically significant toxicities emerged with the use of ABC/3TC/ ZDV+TDF. However, adverse events accounted for 27% (14/52) of all study discontinuations. Of the 14 participants who withdrew from the study because of adverse events, approximately half withdrew due to suspected ABC HSR (8/14, or 57%). Although suspected ABC HSR was the most common reason for study discontinuation (15% or 8/52), the overall ABC HSR rate (8/123, or 6.5%) is comparable to that observed in clinical studies of ABC given once or twice daily. 4, 5, 29, 30 A minority of adverse events or toxicities reported may be attributable to ZDV (≤2%, 3/123).
One of the more interesting results in this study was the modest improvement in fasting serum lipid concentrations, as evidenced by the decrease from baseline values in total cholesterol, LDL cholesterol, and triglycerides. HDL cholesterol was slightly elevated from baseline. These findings compare favorably with those reported for participants treated with ABC/3TC/ZDV for 96 weeks in a prospective randomized study of hyperlipidemia in antiretroviral-naïve individuals 31 as well as those reported for participants treated with TDF+3TC+efavirenz for 144 weeks 32 or with TDF+emitracitabine+efavirenz for 48 weeks. 33 Results from A5095 indicated that among those on ABC/3TC/ZDV there were minimal to no shortterm changes in lipid or glucose parameters over 24 weeks, whereas a moderate increase in triglycerides and a slight increase in LDL cholesterol were observed over 72 weeks among those in whom TDF was added. 34 Toxicities associated with the long-term use of NRTIs may be caused by the inhibition of mitochondrial DNA synthesis and depletion, resulting in cellular and tissue-specific toxicity. 35, 36 No evidence of mitochondrial toxicity was seen in the present study as mitochondrial DNA levels were essentially unchanged.
CONCLUSION
The high rate of premature study discontinuations contributed to the overall low virologic response rates observed with the oncedaily ABC/3TC/ZDV+TDF regimen; however, the regimen was not associated with the high rates of virologic failure previously observed with TDF+ABC/3TC. For those participants who remained on study, the once-daily regimen of ABC/ 3TC/ZDV+TDF provided good antiviral efficacy and a favorable lipid profile. The broader utility of this regimen for initial therapy merits additional study given the need for all-NRTI regimens for certain patient groups where NNRTIs and PIs cannot be conveniently used. ABC/3TC/ZDV+TDF is an attractive class-sparing regimen for several reasons: it has a low pill burden (total of three tablets daily), can be dosed without regard to food, has few drug interactions, and may be associated with a favorable lipid profile after 48 weeks of treatment. ABC/3TC/ZDV+TDF may be an especially attractive therapeutic option for HIV-infected patients with psychiatric conditions or hepatitis B or hepatitis C coinfection and for those being treated with rifampin-based tuberculosis regimens or methadone. Thus, a fully powered study of ABC/ 3TC/ZDV given twice daily in combination with TDF once daily is warranted to establish the role of this quadruple-NRTI regimen as initial therapy in antiretroviral-naïve patients.
